<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Where There&apos;s Smoke, There&apos;s Fire? Significance of Atrial Fibrillation in Young Patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, MA</roleName><forename type="first">Alexander</forename><surname>Wutzler</surname></persName>
							<email>alexander.wutzler@ruhr-uni-bochum.de</email>
						</author>
						<author>
							<persName><forename type="first">Sophie</forename><surname>Von Ulmenstein</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philipp</forename><surname>Attanasio</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Martin</forename><surname>Huemer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Abdul</forename><forename type="middle">Shokor</forename><surname>Parwani</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Katharina</forename><surname>Völk</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Florian</forename><surname>Blaschke</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Leif-Hendrik</forename><surname>Boldt</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Wilhelm</forename><surname>Haverkamp</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Cardiovascular Center St</orgName>
								<orgName type="institution" key="instit2">Josef Hospital Ruhr University Bochum Gudrunstrasse 56</orgName>
								<address>
									<postCode>44791</postCode>
									<settlement>Bochum</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Cardiovascular Center (Wutzler)</orgName>
								<orgName type="institution" key="instit1">St. Josef Hospital</orgName>
								<orgName type="institution" key="instit2">Ruhr University Bochum</orgName>
								<address>
									<settlement>Bochum</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Where There&apos;s Smoke, There&apos;s Fire? Significance of Atrial Fibrillation in Young Patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6802F11351D96A0A0D5F40433354C34E</idno>
					<idno type="DOI">10.1002/clc.22516</idno>
					<note type="submission">Received: October 18, 2015 Accepted with revision: November 25, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Atrial fibrillation (AF), a disease of the elderly, occasionally occurs at younger age.</s><s>Pathophysiology of AF in younger patients is diverse, including channelopathies and cardiomyopathies.</s><s>Data on the significance and complications of AF in young patients are scarce.</s><s>Hypothesis: Atrial fibrillation is the first manifestation of cardiovascular disease (CVD) in young patients.</s><s>Methods: From 11 888 patients in a university hospital database, patients age ≤35 years were identified.</s><s>A composite of stroke/transient ischemic attack, thromboembolic events, major bleeding, and death was the primary endpoint.</s><s>Stroke/transient ischemic attack, thromboembolic events, major bleeding, death, AF during follow-up, diagnosis of arrhythmia other than AF, and new diagnosis of any CVD were secondary endpoints.</s><s>Endpoints were compared between patients with and without comorbidities.</s><s>Results: We identified 124 patients (29.1± 5 years).</s><s>Of those, 84 were followed over 48.4 ± 39.8 months.</s><s>Comorbidities were present in 40.5%.</s><s>Incidence of the primary endpoint was not different between the groups.</s><s>Arrhythmias other than AF were more common in patients without comorbidities (36% vs 14.7%; P = 0.032).</s><s>A supraventricular tachycardia (SVT) was found in 57.1% of patients who underwent electrophysiological testing and was treated with catheter ablation.</s><s>None of those patients had AF during follow-up.</s><s>Conclusions: Atrial fibrillation occurs in young patients with and without structural heart disease.</s><s>Young AF patients without comorbidities rarely develop CVD during the first years after diagnosis.</s><s>Yet, an SVT is found in a high proportion of young AF patients; AF may be first manifestation of SVT.</s><s>Therefore, young patients should undergo further evaluation for SVT</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Atrial fibrillation (AF), the most common cardiac arrhythmia in adults, is usually prevalent in patients age ≥60 years. <ref type="bibr" target="#b0">1</ref> However, a number of patients with AF are presenting with the first episode at younger age. <ref type="bibr" target="#b1">2</ref> In contrast to older patients, where fibrosis, atrial dilation, and oxidative stress are key mechanisms, <ref type="bibr" target="#b2">3</ref> -6 pathophysiology of AF in younger patients is diverse.</s><s>Causes for AF in the young include ionchannel disease, cardiomyopathy, and genetic factors. <ref type="bibr" target="#b6">7</ref></s><s>-10 Particularly, the role of AF as a first manifestation of a clinically silent cardiac disease has been discussed. <ref type="bibr" target="#b11">11,</ref><ref type="bibr" target="#b12">12</ref></s><s>urthermore, the course and complications of AF in daily practice have not been investigated for younger patients.</s></p><p><s>The authors have no funding, financial relationships, or conflicts of interest to disclose.</s></p><p><s>Because the prevalence of AF in persons age &lt;40 years is 0.5%, 2 the absolute number of young patients in different studies and registries is low and data on AF in persons age &lt;35 years are scarce.</s><s>The purpose of our study was to evaluate the clinical significance of AF in young adults.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>From 11 888 patients with AF who presented to the university arrhythmia center at the Charit é-Universitätsmedizin Berlin between January 2001 and December 2014, all patients age ≤35 years were analyzed.</s><s>The study complies with the Declaration of Helsinki and was approved by the ethics committee of the Charit é-Universitätsmedizin Berlin.</s></p><p><s>At baseline, AF type according to actual guidelines and symptoms using the European Heart Rhythm Association (EHRA) classification, comorbidities, treatment strategy (rate vs rhythm control), anticoagulant treatment, stroke, and bleeding risk were assessed.</s><s>Stroke and bleeding risk were determined using the CHA 2 DS 2 -VASc and HAS-BLED scores, respectively.</s><s>A composite of stroke/transient ischemic attack (TIA), thromboembolic events, major bleeding, and death from any cause was the primary endpoint.</s><s>Follow-up visits were scheduled at the discretion of the treating physician but at least once a year.</s><s>Stroke/TIA, thromboembolic events, major bleeding, death, AF during follow-up, diagnosis of arrhythmia other than AF, and new diagnosis of any cardiovascular disease were secondary endpoints.</s><s>Endpoints were assessed both at scheduled an unscheduled visits during follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Discrete variables are presented as numbers and percentages; continuous variables are presented as mean and SD.</s><s>The Mann-Whitney U test (for skewed data) or the t test were used as appropriate for comparison of continuous variables.</s><s>The χ 2 test was used to analyze discrete variables.</s><s>All analyses were performed using SPSS software version 22.0 (IBM Corp., Armonk, NY).</s><s>A P value of &lt;0.05 was considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>A total of 11 888 patients that presented to our hospital center between January 2001 and December 2014 were included in the registry.</s><s>Of those, 124 (1.04%) were age ≤35 years at the time of their first presentation, with a mean age of 29.1 5 years.</s><s>Patient characteristics and medications are presented in Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>Of all patients, 42.7% had AF in the absence of any comorbidity.</s><s>The majority of patients had first diagnosed (21%) or paroxysmal AF (50%).</s><s>In our center, 45.2% of the patients presented with symptoms, mainly in EHRA class II.</s><s>Rhythm control was chosen as the treatment strategy in 56 (45.2%) of the patients.</s><s>In CHA 2 DS 2 -VASc and HAS-BLED were 0.7 ± 1 and 0.5 ± 0.6, respectively.</s><s>Forty-five patients (36.3%) received oral anticoagulation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Follow-up Results</head><p><s>Of all patients from this age group, 84 were followed over 48.4 ± 39.8 months, with 8.2 ± 8.8 visits during follow-up.</s><s>During follow-up, 8 (9.5%) patients reached the primary composite endpoint.</s><s>Four patients experienced a major bleeding (1 massive groin hematoma after catheter ablation, 1 pulmonary bleeding due to pneumonia with respiratory failure, 1 hemorrhagic ovarian cyst, and 1 intra-abdominal bleeding after abdominal surgery).</s><s>Two patients died during follow-up (1 heart failure due to hypertrophic cardiomyopathy, 1 pneumonia with respiratory failure).</s><s>Arrhythmias other than AF were observed in 27.4%.</s><s>Stroke/TIA and heart failure systemic embolism were not observed during the study.</s><s>In none of the patients was a cardiovascular disease newly diagnosed during follow-up.</s><s>Complete results for primary and secondary endpoints are presented in Table <ref type="table" target="#tab_1">2</ref>.</s></p><p><s>Further analysis revealed significant differences between patients with AF associated with cardiovascular comorbidities compared with those with without comorbidities (Table <ref type="table" target="#tab_2">3</ref>).</s><s>The CHA 2 DS 2 -VASc and HAS-BLED scores were lower in patients without comorbidities.</s><s>Yet, in this cohort of young patients, score values were low in both groups and no significant differences in oral anticoagulation treatment were found.</s></p><p><s>Arrhythmias other than AF were more common in patients without comorbidities (36% vs 14.7%), with a proportion of 24% having a supraventricular tachycardia (SVT), namely AV reentry tachycardia (AVRT) or AV node reentry tachycardia (AVNRT; Table <ref type="table" target="#tab_2">3</ref>).</s><s>Diagnosis of SVT in those patients was confirmed during electrophysiology study and successfully treated with catheter ablation in all cases.</s></p><p><s>Two patients died, both from the group of patients with comorbidities (1 heart failure, 1 pneumonia).</s><s>No case of unexplained death occurred in any of the groups, nor was an ion-channel disease diagnosed during follow-up.</s><s>One case of sustained ventricular tachycardia was observed.</s><s>The patient had been diagnosed with hypertrophic cardiomyopathy earlier and was treated with an implantable cardioverterdefibrillator.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>We present data on the incidence and complications of AF in patients ≤35 years.</s><s>Atrial fibrillation is associated with structural heart disease in this age group in 57.3% of the patients.</s><s>Incidence of stroke or systemic embolism is low in patients with and without comorbidities.</s><s>Yet, death and major bleeding occurred in 2.4% and 4.8%, respectively.</s><s>Surprisingly, a relatively high incidence of arrhythmia other than AF (27.4%) was observed during followup.</s><s>Subgroup analysis of patients with and without comorbidities revealed that 36% of patients without comorbidities had an arrhythmia other than AF during follow-up.</s><s>In patients without comorbidities undergoing electrophysiology testing, an SVT was found in 57.1% of the cases.</s></p><p><s>It has been previously proposed that AF in the absence of overt cardiac disease may be the first manifestation of another underlying disease (eg, an ionchannel disease [Brugada syndrome], long QT syndrome) or a cardiomyopathy. <ref type="bibr" target="#b11">11</ref></s><s>-13 None of the patients in our study was newly diagnosed with a channelopathy or a cardiomyopathy during follow-up.</s><s>No sudden or unexplained death occurred.</s><s>In contrast, a relatively high incidence of SVT was observed in patients undergoing electrophysiology testing and catheter ablation.</s><s>In fact, in 12 of 21 patients without comorbidities (57.1%) who underwent catheter ablation, an SVT was detected.</s><s>Unlike typical atrial flutter, which is found in a high proportion of AF patients, <ref type="bibr" target="#b14">14</ref> young patients with SVT only rarely present with AF episodes.</s><s>An association of SVT and AF is reported in the literature. <ref type="bibr" target="#b15">15</ref></s><s>-17 However, patients with SVT and AF are usually older than the patients in our study, and AF is more common in patients with AVRT compared with AVNRT. <ref type="bibr" target="#b15">15,</ref><ref type="bibr" target="#b16">16</ref></s><s>he patients undergoing electrophysiology testing in our study were originally referred to our center for pulmonary vein isolation (PVI) as treatment of AF.</s><s>The AVRT or AVNRT were diagnosed during routine diagnostic tests at the beginning of the procedure.</s><s>When diagnosis of SVT was confirmed, ablation of accessory pathway or slow pathway modification was performed and AF was not targeted in the ablation procedure.</s><s>Patients were discharged without further treatment for AF.</s><s>None of the patients undergoing catheter ablation of SVT had recurrence of any arrhythmia during follow-up.</s><s>Therefore, AF may be triggered by SVT episodes and secondary to the underlying SVT in those patients.</s><s>Yet, we cannot rule out coincidence of AF and SVT in those patients.</s><s>The rationale for treatment of SVT rather than PVI was to start with a relatively short and safe procedure in these cases and decide the need for PVI based on the clinical follow-up.</s><s>Notably, we cannot rule out presence of SVT as trigger for AF in the vast majority of patients, because we did not routinely perform electrophysiology studies in our cohort.</s><s>To our concern, it is of high clinical interest to determine the presence of AVRT or AVNRT in this special subset of AF patients.</s><s>Young patients with AF secondary to SVT, once treated with catheter ablation, may never have episodes of any arrhythmia again.</s><s>Others may have coincidentally SVT and AF.</s><s>The latter may require further treatment for AF despite successful ablation of SVT, including anticoagulant treatment as appropriate and PVI.</s><s>In any case, thorough diagnostic testing is required before young AF patients are referred for PVI, as complication rates for PVI are much higher than for SVT ablation.</s><s>A PVI must be avoided in those patients who do not need it.</s><s>An electrophysiology study may be considered in the routine workup in patients age ≤35 years without comorbidities who present with recurrent episodes of AF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Limitations</head><p><s>There are limitations to our study that should be acknowledged.</s><s>First, nonrandomized observational protocol was used.</s><s>Second, the number of patients in follow-up is relatively small, and a number of patients were lost to follow-up.</s><s>It would be particularly interesting to ascertain whether these patients did not present to follow-up visits because they had no recurrence of AF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>Atrial fibrillation occurs in young patients with and without structural heart disease.</s><s>An SVT is found in a high proportion of young AF patients without structural heart disease.</s><s>Atrial fibrillation, therefore, may be the first manifestation of SVT.</s><s>Because curative treatment for SVT, in contrast to AF, is straightforward, young AF patients should undergo further evaluation for SVT.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient Baseline Characteristics BMI, body mass index; CAD, coronary artery disease; CHA 2 DS 2 -VASc, congestive heart failure, HTN, age ≥75 y, DM, stroke/TIA, vascular disease, age 65-74 y, sex category (women); COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DM, diabetes mellitus; EHRA, European Heart Rhythm Association; HAS-BLED, hypertension, abnormal renal or liver function, stroke, bleeding, labile INRs, elderly (age ≥65), drug therapy; HF, heart failure; HR, heart rate; HTN, hypertension; INR, international normalized ratio; LVEF, left ventricular ejection fraction; OAC, oral anticoagulation; SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischemic attack.</s><s>Data are presented as n (%) or mean ± SD.</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell>Value</cell></row><row><cell>No. of patients</cell><cell>124</cell></row><row><cell>Mean age, y</cell><cell>29.1 ± 5</cell></row><row><cell>Male sex</cell><cell>93 (75)</cell></row><row><cell>BMI, kg/m 2</cell><cell>25.9 ± 5</cell></row><row><cell>LVEF, %</cell><cell>54 ± 12.1</cell></row><row><cell>HR, min −1</cell><cell>99.4 ± 39.7</cell></row><row><cell>SBP, mm Hg</cell><cell>122.8 ± 19.3</cell></row><row><cell>DBP, mm Hg</cell><cell>72.8 ± 12</cell></row><row><cell>CHA 2 DS 2 -VASc</cell><cell>0.7 ± 1</cell></row><row><cell>HAS-BLED</cell><cell>0.5 ± 0.6</cell></row><row><cell>Rhythm control</cell><cell>56 (45.2)</cell></row><row><cell>EHRA class</cell><cell></cell></row><row><cell>I</cell><cell>68 (54.8)</cell></row><row><cell>II</cell><cell>45 (36.3)</cell></row><row><cell>III</cell><cell>9 (7.3)</cell></row><row><cell>IV</cell><cell>2 (1.6)</cell></row><row><cell>AF without comorbidity</cell><cell>53 (42.7)</cell></row><row><cell>AF type</cell><cell></cell></row><row><cell>First diagnosed AF</cell><cell>26 (21)</cell></row><row><cell>Paroxysmal AF</cell><cell>62 (50)</cell></row><row><cell>Persistent AF</cell><cell>17 (13.7)</cell></row><row><cell>Permanent AF</cell><cell>3 (2.4)</cell></row><row><cell>Unknown</cell><cell>16 (12.9)</cell></row><row><cell>Comorbidities</cell><cell></cell></row><row><cell>HTN</cell><cell>22 (17.7)</cell></row><row><cell>CAD</cell><cell>3 (2.4)</cell></row><row><cell>HF</cell><cell>14 (11.3)</cell></row><row><cell>Cardiomyopathy</cell><cell>24 (19.4)</cell></row><row><cell>Previous stroke or TIA</cell><cell>6 (4.8)</cell></row><row><cell>DM</cell><cell>2 (1.6)</cell></row><row><cell>Hyperlipoproteinemia</cell><cell>5 (4)</cell></row><row><cell>COPD</cell><cell>1 (0.8)</cell></row><row><cell>Carcinoma</cell><cell>6 (4.8)</cell></row><row><cell>Impaired renal function</cell><cell>7 (5.6)</cell></row><row><cell>Smoker</cell><cell>14 (11.3)</cell></row><row><cell>Medication</cell><cell></cell></row><row><cell>Flecainide</cell><cell>13 (10.5)</cell></row></table><note><p><s>230Clin.</s><s>Cardiol. 39, 4, 229-233 (2016)</s><s>A. Wutzler et al.</s><s>AF in young patients Published online in Wiley Online Library (wileyonlinelibrary.com) DOI:10.1002/clc.22516</s><s>© 2016 Wiley Periodicals, Inc. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ASA, aspirin;</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Outcome During Follow-up</s></p></div></figDesc><table><row><cell>Outcome During</cell></row><row><cell>Follow-up, n = 84</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Outcome During Follow-up Compared Between Patients With AF Associated With Cardiovascular Comorbidities vs AF Patients Without Comorbidities</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Table 3. Continued</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>AF Associated</cell><cell>AF Without</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>With Comorbidities,</cell><cell>Comorbidities,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n = 34</cell><cell>n = 50</cell><cell>P Value</cell></row><row><cell></cell><cell>AF Associated With</cell><cell>AF Without</cell><cell></cell><cell>AV reentry tachycardia</cell><cell>1</cell><cell>4</cell><cell></cell></row><row><cell></cell><cell>Comorbidities,</cell><cell>Comorbidities,</cell><cell></cell><cell>AV node reentry</cell><cell>-</cell><cell>8</cell><cell></cell></row><row><cell></cell><cell>n = 34</cell><cell>n = 50</cell><cell>P Value</cell><cell>tachycardia</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CHA 2 DS 2 -VASc score</cell><cell>1 ± 1.1</cell><cell>0.3 ± 0.6</cell><cell>&lt;0.001 a</cell><cell>New diagnosis of CVD</cell><cell>-</cell><cell>-</cell><cell>NA</cell></row><row><cell>HAS-BLED score</cell><cell>0.7 ± 0.7</cell><cell>0.4 ± 0.5</cell><cell>0.023 a</cell><cell cols="4">Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">CHA 2 DS 2 -VASc, congestive heart failure, HTN, age ≥75 y, DM,</cell></row><row><cell>Comorbidities</cell><cell></cell><cell></cell><cell></cell><cell cols="4">stroke/TIA, vascular disease, age 65-74 y, sex category (women); CVD,</cell></row><row><cell>CAD</cell><cell>2 (5.9)</cell><cell>-</cell><cell></cell><cell cols="4">cardiovascular disease; DM diabetes mellitus; ECG, electrocardiogram; HAS-BLED, hypertension, abnormal renal or liver function, stroke,</cell></row><row><cell>HTN</cell><cell>13 (38.2)</cell><cell>-</cell><cell></cell><cell cols="4">bleeding, labile INRs, elderly (age ≥65), drug therapy; HTN, hypertension; INR, international normalized ratio; NA, not applicable;</cell></row><row><cell>Mechanical valve replacement</cell><cell>6 (17.6)</cell><cell>-</cell><cell></cell><cell cols="4">RV, right ventricular; SD, standard deviation; SE, systemic embolism; SVT, supraventricular tachycardia; TIA, transient ischemic attack; VT, ventricular tachycardia.</cell></row><row><cell>Hypertrophic</cell><cell>7 (20.6)</cell><cell>-</cell><cell></cell><cell cols="2">Data are presented as n (%) or mean ± SD.</cell><cell></cell><cell></cell></row><row><cell>cardiomyopathy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dilated cardiomyopathy</cell><cell>3 (8.8)</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Takotsubo</cell><cell>2 (5.9)</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>cardiomyopathy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arrhythmogenic RV</cell><cell>1 (2.9)</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>cardiomyopathy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Other cardiomyopathy</cell><cell>7 (20.6)</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Anticoagulation</cell><cell>17 (50)</cell><cell>17 (34)</cell><cell>0.14</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vitamin K antagonist</cell><cell>15 (44.1)</cell><cell>13 (26)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Factor Xa inhibitor</cell><cell>2 (5.9)</cell><cell>4 (8)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rhythm control</cell><cell>20 (58.8)</cell><cell>34 (68)</cell><cell>0.39</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Electrical cardioversion</cell><cell>13</cell><cell>17</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Antiarrhythmic drugs</cell><cell>11</cell><cell>8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Catheter ablation</cell><cell>8</cell><cell>21</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study endpoints</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Composite endpoint</cell><cell>5 (14.7)</cell><cell>3 (6)</cell><cell>0.18</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Stroke/TIA</cell><cell>-</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SE</cell><cell>-</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Major bleeding</cell><cell>2 (5.9)</cell><cell>2 (4)</cell><cell>0.69</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Death</cell><cell>2 (5.9)</cell><cell>-</cell><cell>0.049 a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>AF at follow-up</cell><cell>13 (38.2)</cell><cell>10 (20)</cell><cell>0.66</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arrhythmia other</cell><cell>5 (14.7)</cell><cell>18 (36)</cell><cell>0.032 a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>than AF</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Typical atrial flutter</cell><cell>3 (8.8)</cell><cell>6 (12)</cell><cell>0.64</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(ambulatory ECG)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VT (ambulatory ECG)</cell><cell>1 (2.9)</cell><cell>-</cell><cell>0.22</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Induced SVT during</cell><cell>1 (2.9)</cell><cell>12 (24)</cell><cell>0.009 a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>electrophysiology study</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Statistically significant.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">A. Wutzler et al. AF in young patients Published online in Wiley Online Library (wileyonlinelibrary.com) DOI:10.1002/clc.22516 © 2016 Wiley Periodicals, Inc.</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Havmoeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narayanan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Study. Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="837" to="847" />
			<date type="published" when="2010">2010. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Atrial fibrillation: epidemiology, prognosis and therapy</title>
		<author>
			<persName><forename type="first">H</forename><surname>Rutzen-Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Reynolds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Minerva Med</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="187" to="207" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Aging-related increase to inducible atrial fibrillation in the rat model</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miyauchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="801" to="808" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Verheule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tuyls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Hunnik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Arrhythm Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="590" to="599" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Su</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1310" to="1318" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Tsao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="190" to="196" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter</title>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Macle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Cardiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="60" to="66" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Genes and atrial fibrillation: a new look at an old problem</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fatkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Otway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Vandenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="782" to="792" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Clinical course of hypertrophic cardiomyopathy in a regional United States cohort</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Maron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Casey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Poliac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page">2288</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>published correction appears in</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page" from="650" to="655" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Genomic medicine and atrial fibrillation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mestroni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="2193" to="2196" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance</title>
		<author>
			<persName><forename type="first">C</forename><surname>Pappone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Radinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Manguso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2985" to="2992" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Atrial fibrillation in cardiac channelopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Thejus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Francis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Indian Pacing Electrophysiol J</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="342" to="350" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Priori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Wilde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Horie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Rhythm</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1932" to="1963" />
			<date type="published" when="2013-06">2013. June 2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Long-term outcome of patients after successful radiofrequency ablation for typical atrial flutter</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Gillian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Zakaib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fuller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pacing Clin Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="53" to="58" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>part 1</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Relationship between accessory pathway location and occurrence of atrial fibrillation in patients with atrioventricular reentrant tachycardia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Clin Cardiol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="196" to="199" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Tai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="2023" to="2032" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Clair</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="984" to="988" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
